SlideShare a Scribd company logo
1 of 3
Download to read offline
Morbidity and Mortality Weekly Report
Weekly / Vol. 68 / No. 18	 May 10, 2019
INSIDE
416	 Disparities in Incidence of Human
Immunodeficiency Virus Infection Among Black and
White Women — United States, 2010–2016
419	 Racial Disparities in Mortality Associated with
Systemic Lupus Erythematosus — Fulton and
DeKalb Counties, Georgia, 2002–2016
423	 Vital Signs: Pregnancy-Related Deaths, United States,
2011–2015, and Strategies for Prevention, 13 States,
2013–2017
430	QuickStats
Continuing Education examination available at
https://www.cdc.gov/mmwr/cme/conted_info.html#weekly.
U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
Hepatitis Awareness Month and
Testing Day — May 2019
May is designated as Hepatitis Awareness Month,
and May 19 is Hepatitis Testing Day. Hepatitis B and
hepatitis C, the most common types of viral hepatitis in
the United States, can cause chronic infections, and many
persons remain unaware of their infection until serious
complications occur. In 2016, an estimated 862,000
and 2.4 million persons were living with hepatitis B and
hepatitis C, respectively, despite availability of a vaccine
and effective treatment for hepatitis B and a cure for
hepatitis C (1,2).
Although hepatitis A is preventable through vaccina-
tion, multiple states have had outbreaks since 2016, with
unprecedented large numbers of cases and person-to-
person spread (primarily among persons who use drugs or
experience homelessness). A report in this issue of MMWR
summarizes this resurgence of hepatitis A among unvac-
cinated adults at risk (3).
New cases of hepatitis C are also increasing; during
2010–2016, they increased 3.5-fold, mostly among young
adults (4). Recent increases in viral hepatitis infections,
many attributed to surges in injection-drug use (4), high-
light the importance of acknowledging and combatting the
infectious disease consequences of the nation’s opioid crisis.
References
1.	Patel EU, Thio CL, Boon D, Thomas DL, Tobian AAR. Prevalence
of hepatitis B and hepatitis D virus infections in the United States,
2011–2016. Clin Infect Dis 2019.https://doi.org/10.1093/cid/ciz001
2.	Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating
prevalence of hepatitis C virus infection in the United States,
2013–2016. Hepatology 2019;69:1020–31. https://doi.
org/10.1002/hep.30297
3.	Foster M, Hofmeister MG, Kupronis BA, et al. Increase in hepatitis A
virus infections—United States, 2013–2018. MMWR Morb Mortal
Wkly Rep 2019;68:413–5.
4.	CDC. Viral hepatitis surveillance—United States, 2016. Atlanta,
GA: US Department of Health and Human Services, CDC; 2016.
https://www.cdc.gov/hepatitis/statistics/2016surveillance/index.htm
Increase in Hepatitis A Virus
Infections — United States,
2013–2018
Monique A. Foster, MD1; Megan G. Hofmeister, MD1;
Benjamin A. Kupronis, MPH1; Yulin Lin, MD1; Guo-Liang Xia, MD1;
Shaoman Yin, PhD1; Eyasu Teshale, MD1
Hepatitis A virus (HAV) is primarily transmitted fecal-orally
after close contact with an infected person (1); it is the most
common cause of viral hepatitis worldwide, typically causing
acute and self-limited symptoms, although rarely liver failure
and death can occur (1). Rates of hepatitis A had declined
by approximately 95% during 1996–2011; however, during
2016–2018, CDC received approximately 15,000 reports of
HAV infections from U.S. states and territories, indicating
a recent increase in transmission (2,3). Since 2017, the vast
majority of these reports were related to multiple outbreaks
of infections among persons reporting drug use or homeless-
ness (4). In addition, increases of HAV infections have also
occurred among men who have sex with men (MSM) and,
to a much lesser degree, in association with consumption of
imported HAV-contaminated food (5,6). Overall, reports of
hepatitis A cases increased 294% during 2016–2018 compared
Morbidity and Mortality Weekly Report
414	 MMWR / May 10, 2019 / Vol. 68 / No. 18 US Department of Health and Human Services/Centers for Disease Control and Prevention
The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC),
U.S. Department of Health and Human Services, Atlanta, GA 30329-4027.
Suggested citation: [Author names; first three, then et al., if more than six.] [Report title]. MMWR Morb Mortal Wkly Rep 2019;68:[inclusive page numbers].
Centers for Disease Control and Prevention
Robert R. Redfield, MD, Director
Anne Schuchat, MD, Principal Deputy Director
Chesley L. Richards, MD, MPH, Deputy Director for Public Health Science and Surveillance
Rebecca Bunnell, PhD, MEd, Director, Office of Science
Barbara Ellis, PhD, MS, Acting Director, Office of Science Quality, Office of Science
Michael F. Iademarco, MD, MPH, Director, Center for Surveillance, Epidemiology, and Laboratory Services
MMWR Editorial and Production Staff (Weekly)
Charlotte K. Kent, PhD, MPH, Editor in Chief
Jacqueline Gindler, MD, Editor
Mary Dott, MD, MPH, Online Editor
Terisa F. Rutledge, Managing Editor
Douglas W. Weatherwax, Lead Technical Writer-Editor
Glenn Damon, Soumya Dunworth, PhD, Teresa M. Hood, MS,
Technical Writer-Editors
Martha F. Boyd, Lead Visual Information Specialist
Maureen A. Leahy, Julia C. Martinroe,
Stephen R. Spriggs, Tong Yang,
Visual Information Specialists
Quang M. Doan, MBA, Phyllis H. King,
Terraye M. Starr, Moua Yang,
Information Technology Specialists
MMWR Editorial Board
Timothy F. Jones, MD, Chairman
Matthew L. Boulton, MD, MPH
Virginia A. Caine, MD
Katherine Lyon Daniel, PhD
Jonathan E. Fielding, MD, MPH, MBA
David W. Fleming, MD
William E. Halperin, MD, DrPH, MPH
Robin Ikeda, MD, MPH
Phyllis Meadows, PhD, MSN, RN
Jewel Mullen, MD, MPH, MPA
Jeff Niederdeppe, PhD
Patricia Quinlisk, MD, MPH
Stephen C. Redd, MD
Patrick L. Remington, MD, MPH
Carlos Roig, MS, MA
William Schaffner, MD
Morgan Bobb Swanson, BS
with 2013–2015. During 2016–2018, CDC tested 4,282
specimens, of which 3,877 (91%) had detectable HAV RNA;
565 (15%), 3,255 (84%), and 57 (<1%) of these specimens
were genotype IA, IB, or IIIA, respectively. Adherence to the
Advisory Committee on Immunization Practices (ACIP)
recommendations to vaccinate populations at risk can help
control the current increases and prevent future outbreaks of
hepatitis A in the United States (7).
Hepatitis A infections among persons who meet the Council
of State andTerritorial Epidemiologists (CSTE) hepatitis A case
definition (https://wwwn.cdc.gov/nndss/conditions/hepatitis-
a-acute/) are notified to CDC through the National Notifiable
Diseases Surveillance System (NNDSS). Cases reported to
CDC through NNDSS during 2013–2018 were used to
calculate percent change (2013–2015 versus 2016–2018) by
state and mapped using RStudio software (version 1.2.1335;
RStudio, Inc.). Serum specimens from CSTE confirmed cases
submitted to the CDC laboratory were tested for HAV RNA by
polymerase chain reaction, and isolated virus was amplified to
characterize a 315–base-pair fragment of the VP1/P2B region,
which defines the genotype of the virus.
Overall, reports of hepatitis A cases increased 294% during
2016–2018 compared with 2013–2015 (Figure). Eighteen
states had lower case counts during 2016–2018 compared
with 2013–2015. Nine states and Washington, DC had an
increase of approximately 500%. During 2013–2018, 4,508
HAV anti-immunoglobulin M–positive specimens under-
went additional testing at CDC. During 2013–2015, 226
specimens underwent additional testing, of which 197 (87%)
had detectable HAV RNA; of the RNA-positive specimens, 76
(39%), 121 (61%), and 0 (0%) tested positive for a genotype
IA, IB, or IIIA viral strain, respectively. In comparison, 4,282
specimens were tested by CDC during 2016–2018, of which
3,877 (91%) had detectable HAV RNA; 565 (15%), 3,255
(84%), and 57 (<1%) of these specimens were genotype IA,
IB, or IIIA, respectively.
Discussion
The number of hepatitis A infections reported to CDC
increased during 2016–2018, along with the number of
specimens from infected persons submitted to CDC for
additional testing. In the past, outbreaks of hepatitis A virus
infections occurred every 10–15 years and were associated
with asymptomatic children (8). With the widespread adop-
tion of universal childhood vaccination recommendations
(https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5507a1.
htm), asymptomatic children are no longer the main drivers
of hepatitis A outbreaks (3,9). Although the overall incidence
rate of HAV infections has decreased within all age groups, a
large population of susceptible, unvaccinated adults who were
not infected by being exposed to the virus during childhood
remain vulnerable to infection by contaminated foods (typi-
cally imported from countries with endemic HAV transmis-
sion) and recently, on a much larger scale, through behaviors
that increase risk for infection in certain vulnerable popula-
tions, such as drug use (3).
Morbidity and Mortality Weekly Report
MMWR / May 10, 2019 / Vol. 68 / No. 18	 415US Department of Health and Human Services/Centers for Disease Control and Prevention
FIGURE. Percent change in reported hepatitis A infections, by
state — National Notifiable Diseases Surveillance System, United
States, 2013–2015 and 2016–2018*
>500
>100–500
>0–100
−100–0
DC
Abbreviation: DC = District of Columbia.
*	2017 and 2018 case counts are provisional.
Increasingly, molecular epidemiology is employed by public
health laboratories to better characterize hepatitis A transmis-
sion patterns. When combined with reliable epidemiologic
data, these laboratory data can be used to identify transmission
networks and confirm the source of exposure during common-
source outbreaks, facilitating prompt and effective public
health response. Historically, genotype IA has been the most
common genotype circulating in North and South America.
During 2013–2018, HAV genotype IB predominated in the
United States. Increasing numbers of genotype IIIA were seen,
a genotype that is considered rare in the United States.
Decreasing new infections from hepatitis A virus can be
achieved and sustained by maintaining a high level of popu-
lation immunity through vaccination. There is no universal
vaccination recommendation for adults in the United States;
however, ACIP does recommend vaccination for adults who
plan travel to HAV-endemic countries, MSM, persons who
use drugs, persons with chronic liver disease, and recently,
persons experiencing homelessness (7). Continued efforts to
increase hepatitis A vaccination coverage among the ACIP-
recommended risk groups is vital to halting the current hepa-
titis A outbreaks and reducing overall hepatitis A incidence in
the United States.
Acknowledgments
Members of the Division of Viral Hepatitis Laboratory, Division
of Viral Hepatitis HAV Incident Management Team, Food and
Drug Administration CORE Signals Teams; state and local health
departments; medical and mental health partners; corrections
partners; syringe service providers.
Summary
What is already known about this topic?
Hepatitis A is a vaccine-preventable viral infection of the liver
that is primarily transmitted through consumption of micro-
scopic amounts of feces.
What is added by this report?
During 2016–2018, reports of hepatitis A infections in the
United States increased by 294% compared with 2013–2015,
related to outbreaks associated with contaminated food items,
among men who have sex with men, and primarily, among
persons who report drug use or homelessness.
What are the implications for public health practice?
Increasing vaccination among groups at risk for hepatitis A infection
might halt ongoing outbreaks and prevent future outbreaks.
	1Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD,
and TB Prevention, CDC.
Corresponding author: Monique A. Foster, ydg9@cdc.gov, 404-718-8561.
All authors have completed and submitted the ICMJE form for
disclosure of potential conflicts of interest. No potential conflicts of
interest were disclosed.
References
1.	Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A:
epidemiology and prevention in developing countries. World J Hepatol
2012;4:68–73. https://doi.org/10.4254/wjh.v4.i3.68
2.	CDC. Viral hepatitis surveillance, United States 2016. Atlanta, GA: US
Department of Health and Human Services, CDC; 2017. https://www.cdc.
gov/hepatitis/statistics/2016surveillance/pdfs/2016HepSurveillanceRpt.pdf
3.	CDC. National notifiable infectious diseases: weekly tables, 2018. Atlanta,
GA: US Department of Health and Human Services, CDC; 2018. https://
wonder.cdc.gov/nndss/static/2018/52/2018-52-table2H-H.pdf
4.	Foster M, Ramachandran S, Myatt K, et al. Hepatitis A virus outbreaks
associated with drug use and homelessness—California, Kentucky,
Michigan, and Utah, 2017. MMWR Morb Mortal Wkly Rep
2018;67:1208–10. https://doi.org/10.15585/mmwr.mm6743a3
5.	Viray MA, Hofmeister MG, Johnston DI, et al. Public health investigation
and response to a hepatitis A outbreak from imported scallops consumed
raw—Hawaii, 2016. Epidemiol Infect 2018;147:1–8.
6.	Latash J, Dorsinville M, Del Rosso P, et al. Notes from the field: increase
in reported hepatitis A infections among men who have sex with men—
New York City, January–August 2017. MMWR Morb Mortal Wkly Rep
2017;66:999–1000. https://doi.org/10.15585/mmwr.mm6637a7
7.	Doshani M, Weng M, Moore KL, Romero JR, Nelson NP.
Recommendations of the Advisory Committee on Immunization Practices
for use of hepatitis A vaccine for persons experiencing homelessness.
MMWR Morb Mortal Wkly Rep 2019;68:153–6. https://doi.
org/10.15585/mmwr.mm6806a6
8.	MurphyTV, Denniston MM, Hill HA, et al. Progress toward eliminating
hepatitis A disease in the United States. MMWR Suppl 2016;65:29–41.
https://doi.org/10.15585/mmwr.su6501a6
9.	Klevens RM, Denniston MM, Jiles-Chapman RB, Murphy TV.
Decreasing immunity to hepatitis A virus infection among US adults:
findings from the National Health and Nutrition Examination Survey
(NHANES), 1999–2012. Vaccine 2015;33:6192–8. https://doi.
org/10.1016/j.vaccine.2015.10.009

More Related Content

What's hot

Why is autoimmune disease underserved
Why is autoimmune disease underservedWhy is autoimmune disease underserved
Why is autoimmune disease underserved
DrBonnie360
 
Clinical Impact of Data From the CROI 2015,Seattle
Clinical Impact of Data From the CROI 2015,SeattleClinical Impact of Data From the CROI 2015,Seattle
Clinical Impact of Data From the CROI 2015,Seattle
Hivlife Info
 
10.11648.j.ijnfs.20150404.21
10.11648.j.ijnfs.20150404.2110.11648.j.ijnfs.20150404.21
10.11648.j.ijnfs.20150404.21
Ayalew Aklilu
 
CSTE Conference_2015_Poster_Histoplasmosis_Fialkowski_Final
CSTE Conference_2015_Poster_Histoplasmosis_Fialkowski_FinalCSTE Conference_2015_Poster_Histoplasmosis_Fialkowski_Final
CSTE Conference_2015_Poster_Histoplasmosis_Fialkowski_Final
Veronica Fialkowski
 

What's hot (20)

HIV Epidemiology in the Prairies
HIV Epidemiology in the PrairiesHIV Epidemiology in the Prairies
HIV Epidemiology in the Prairies
 
West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases —...
West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases —...West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases —...
West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases —...
 
Why is autoimmune disease underserved
Why is autoimmune disease underservedWhy is autoimmune disease underserved
Why is autoimmune disease underserved
 
Analysis for the global burden of disease study 2016 lancet 2017
Analysis for the global burden of disease study 2016   lancet 2017Analysis for the global burden of disease study 2016   lancet 2017
Analysis for the global burden of disease study 2016 lancet 2017
 
2016HIV_STI_SurveillanceReport
2016HIV_STI_SurveillanceReport2016HIV_STI_SurveillanceReport
2016HIV_STI_SurveillanceReport
 
Epidermiologic pattern of viral hepatitis in afghanistan
Epidermiologic pattern of viral hepatitis in afghanistanEpidermiologic pattern of viral hepatitis in afghanistan
Epidermiologic pattern of viral hepatitis in afghanistan
 
11.13.20 | The Impact of COVID-19 on the Opioid Epidemic
11.13.20 | The Impact of COVID-19 on the Opioid Epidemic11.13.20 | The Impact of COVID-19 on the Opioid Epidemic
11.13.20 | The Impact of COVID-19 on the Opioid Epidemic
 
Obesity in younger than 60 years is a risk factor for Covid-19 Hospital admis...
Obesity in younger than 60 years is a risk factor for Covid-19 Hospital admis...Obesity in younger than 60 years is a risk factor for Covid-19 Hospital admis...
Obesity in younger than 60 years is a risk factor for Covid-19 Hospital admis...
 
Estimating HIV prevalence and risk behaviors of transgender persons in the Un...
Estimating HIV prevalence and risk behaviors of transgender persons in the Un...Estimating HIV prevalence and risk behaviors of transgender persons in the Un...
Estimating HIV prevalence and risk behaviors of transgender persons in the Un...
 
Clinical Impact of Data From the CROI 2015,Seattle
Clinical Impact of Data From the CROI 2015,SeattleClinical Impact of Data From the CROI 2015,Seattle
Clinical Impact of Data From the CROI 2015,Seattle
 
World AIDS Day 2014 HIV and AIDS Awareness Campaigns
World AIDS Day 2014 HIV and AIDS Awareness CampaignsWorld AIDS Day 2014 HIV and AIDS Awareness Campaigns
World AIDS Day 2014 HIV and AIDS Awareness Campaigns
 
Bringing Psoriasis into the Light, Kim kjoeller, Leo Pharma
Bringing Psoriasis into the Light, Kim kjoeller, Leo PharmaBringing Psoriasis into the Light, Kim kjoeller, Leo Pharma
Bringing Psoriasis into the Light, Kim kjoeller, Leo Pharma
 
10.11648.j.ijnfs.20150404.21
10.11648.j.ijnfs.20150404.2110.11648.j.ijnfs.20150404.21
10.11648.j.ijnfs.20150404.21
 
HealthMap.org: Aggregation of Online Media Reports for Global Infectious Dise...
HealthMap.org: Aggregation of Online Media Reports for Global Infectious Dise...HealthMap.org: Aggregation of Online Media Reports for Global Infectious Dise...
HealthMap.org: Aggregation of Online Media Reports for Global Infectious Dise...
 
03.05.21 | Creating an Emergency Response System for Emerging Infectious Dise...
03.05.21 | Creating an Emergency Response System for Emerging Infectious Dise...03.05.21 | Creating an Emergency Response System for Emerging Infectious Dise...
03.05.21 | Creating an Emergency Response System for Emerging Infectious Dise...
 
Onile-ere et al 2016
Onile-ere et al 2016Onile-ere et al 2016
Onile-ere et al 2016
 
Privacy vs. Public Health
Privacy vs. Public HealthPrivacy vs. Public Health
Privacy vs. Public Health
 
CSTE Conference_2015_Poster_Histoplasmosis_Fialkowski_Final
CSTE Conference_2015_Poster_Histoplasmosis_Fialkowski_FinalCSTE Conference_2015_Poster_Histoplasmosis_Fialkowski_Final
CSTE Conference_2015_Poster_Histoplasmosis_Fialkowski_Final
 
Correlation of HIV/TB Using GIS
Correlation of HIV/TB Using GISCorrelation of HIV/TB Using GIS
Correlation of HIV/TB Using GIS
 
05.07.21 | Not the Same Old Blues: Trails of the Efforts to Improve PrEP Upta...
05.07.21 | Not the Same Old Blues: Trails of the Efforts to Improve PrEP Upta...05.07.21 | Not the Same Old Blues: Trails of the Efforts to Improve PrEP Upta...
05.07.21 | Not the Same Old Blues: Trails of the Efforts to Improve PrEP Upta...
 

Similar to USA: Hepatitis A infections rise by nearly 300%

Lisa Barnes PHC6946 Internship Paper
Lisa Barnes PHC6946 Internship PaperLisa Barnes PHC6946 Internship Paper
Lisa Barnes PHC6946 Internship Paper
Lisa Barnes
 
e632 www.thelancet.comhiv Vol 6 September 2019Viewpoi
e632 www.thelancet.comhiv   Vol 6   September 2019Viewpoie632 www.thelancet.comhiv   Vol 6   September 2019Viewpoi
e632 www.thelancet.comhiv Vol 6 September 2019Viewpoi
AlyciaGold776
 
Meghaan Walsh HJS Poster[1]
Meghaan Walsh HJS Poster[1]Meghaan Walsh HJS Poster[1]
Meghaan Walsh HJS Poster[1]
Mary Beth Levin
 
Global HIV cohort studies among IDU and future vaccine trials
Global HIV cohort studies among IDU and future vaccine trialsGlobal HIV cohort studies among IDU and future vaccine trials
Global HIV cohort studies among IDU and future vaccine trials
Thira Woratanarat
 
HIV/Aids Surveillance Systems: Are They Implemented Effectively?
HIV/Aids Surveillance Systems: Are They Implemented Effectively? HIV/Aids Surveillance Systems: Are They Implemented Effectively?
HIV/Aids Surveillance Systems: Are They Implemented Effectively?
Xiaoming Zeng
 
yyoneoka_missedopHPV_2016
yyoneoka_missedopHPV_2016yyoneoka_missedopHPV_2016
yyoneoka_missedopHPV_2016
Yukiko Yoneoka
 
The Future of Nursing Theory Discussion.docx
The Future of Nursing Theory Discussion.docxThe Future of Nursing Theory Discussion.docx
The Future of Nursing Theory Discussion.docx
write4
 
International lancet worldwide burden of hiv in transgender women a systema...
International lancet worldwide burden of hiv in transgender women   a systema...International lancet worldwide burden of hiv in transgender women   a systema...
International lancet worldwide burden of hiv in transgender women a systema...
clac.cab
 
A basic understanding of HIV surveillance
A basic understanding of HIV surveillanceA basic understanding of HIV surveillance
A basic understanding of HIV surveillance
Dr.RAJEEV KASHYAP
 
One global health issue that impacts the international health commun.docx
One global health issue that impacts the international health commun.docxOne global health issue that impacts the international health commun.docx
One global health issue that impacts the international health commun.docx
mccormicknadine86
 

Similar to USA: Hepatitis A infections rise by nearly 300% (20)

Lisa Barnes PHC6946 Internship Paper
Lisa Barnes PHC6946 Internship PaperLisa Barnes PHC6946 Internship Paper
Lisa Barnes PHC6946 Internship Paper
 
e632 www.thelancet.comhiv Vol 6 September 2019Viewpoi
e632 www.thelancet.comhiv   Vol 6   September 2019Viewpoie632 www.thelancet.comhiv   Vol 6   September 2019Viewpoi
e632 www.thelancet.comhiv Vol 6 September 2019Viewpoi
 
Non-invasive Diagnostic Tools: Cardiometabolic Risk Assessment and Prediction
Non-invasive Diagnostic Tools: Cardiometabolic Risk Assessment and PredictionNon-invasive Diagnostic Tools: Cardiometabolic Risk Assessment and Prediction
Non-invasive Diagnostic Tools: Cardiometabolic Risk Assessment and Prediction
 
OUTBREAK REPORT: INFECTIOUS DISEASE.docx
OUTBREAK REPORT: INFECTIOUS DISEASE.docxOUTBREAK REPORT: INFECTIOUS DISEASE.docx
OUTBREAK REPORT: INFECTIOUS DISEASE.docx
 
Meghaan Walsh HJS Poster[1]
Meghaan Walsh HJS Poster[1]Meghaan Walsh HJS Poster[1]
Meghaan Walsh HJS Poster[1]
 
Capstone Powerpoint Presentation
Capstone Powerpoint PresentationCapstone Powerpoint Presentation
Capstone Powerpoint Presentation
 
Global HIV cohort studies among IDU and future vaccine trials
Global HIV cohort studies among IDU and future vaccine trialsGlobal HIV cohort studies among IDU and future vaccine trials
Global HIV cohort studies among IDU and future vaccine trials
 
HATS_Medwiser_A
HATS_Medwiser_AHATS_Medwiser_A
HATS_Medwiser_A
 
HIV/Aids Surveillance Systems: Are They Implemented Effectively?
HIV/Aids Surveillance Systems: Are They Implemented Effectively? HIV/Aids Surveillance Systems: Are They Implemented Effectively?
HIV/Aids Surveillance Systems: Are They Implemented Effectively?
 
Public awareness is a key role to eradicate Hepatitis: A survey to determine ...
Public awareness is a key role to eradicate Hepatitis: A survey to determine ...Public awareness is a key role to eradicate Hepatitis: A survey to determine ...
Public awareness is a key role to eradicate Hepatitis: A survey to determine ...
 
yyoneoka_missedopHPV_2016
yyoneoka_missedopHPV_2016yyoneoka_missedopHPV_2016
yyoneoka_missedopHPV_2016
 
The Future of Nursing Theory Discussion.docx
The Future of Nursing Theory Discussion.docxThe Future of Nursing Theory Discussion.docx
The Future of Nursing Theory Discussion.docx
 
Global Medical Cures™ | HIV TESTING IN USA
Global Medical Cures™ | HIV TESTING IN USAGlobal Medical Cures™ | HIV TESTING IN USA
Global Medical Cures™ | HIV TESTING IN USA
 
Hiv
HivHiv
Hiv
 
semo2036
semo2036semo2036
semo2036
 
International lancet worldwide burden of hiv in transgender women a systema...
International lancet worldwide burden of hiv in transgender women   a systema...International lancet worldwide burden of hiv in transgender women   a systema...
International lancet worldwide burden of hiv in transgender women a systema...
 
A basic understanding of HIV surveillance
A basic understanding of HIV surveillanceA basic understanding of HIV surveillance
A basic understanding of HIV surveillance
 
One global health issue that impacts the international health commun.docx
One global health issue that impacts the international health commun.docxOne global health issue that impacts the international health commun.docx
One global health issue that impacts the international health commun.docx
 
Cancer Biomarkers Research, HPV and Cancer, HPV Vaccine
Cancer Biomarkers Research, HPV and Cancer, HPV VaccineCancer Biomarkers Research, HPV and Cancer, HPV Vaccine
Cancer Biomarkers Research, HPV and Cancer, HPV Vaccine
 
journal.pntd.0000877.PDF
journal.pntd.0000877.PDFjournal.pntd.0000877.PDF
journal.pntd.0000877.PDF
 

More from Δρ. Γιώργος K. Κασάπης

Policyholder behavior to close the protection gap
Policyholder behavior to close the protection gap Policyholder behavior to close the protection gap
Policyholder behavior to close the protection gap
Δρ. Γιώργος K. Κασάπης
 

More from Δρ. Γιώργος K. Κασάπης (20)

The economics of climate change: no action not an option
The economics of climate change: no action not an optionThe economics of climate change: no action not an option
The economics of climate change: no action not an option
 
Promise and peril: How artificial intelligence is transforming health care
Promise and peril: How artificial intelligence is transforming health carePromise and peril: How artificial intelligence is transforming health care
Promise and peril: How artificial intelligence is transforming health care
 
Amnesty International: Death sentences and executions 2020
Amnesty International: Death sentences and executions 2020 Amnesty International: Death sentences and executions 2020
Amnesty International: Death sentences and executions 2020
 
Aviva: How we live
Aviva: How we liveAviva: How we live
Aviva: How we live
 
Policyholder behavior to close the protection gap
Policyholder behavior to close the protection gap Policyholder behavior to close the protection gap
Policyholder behavior to close the protection gap
 
Regulatory Considerations for Digital Insurance Business Models
Regulatory Considerations for Digital Insurance Business ModelsRegulatory Considerations for Digital Insurance Business Models
Regulatory Considerations for Digital Insurance Business Models
 
Interner of Things Iinsurance gateway
Interner of Things Iinsurance gateway Interner of Things Iinsurance gateway
Interner of Things Iinsurance gateway
 
Transpareny international 2021 report: paying for views
Transpareny international 2021 report: paying for views Transpareny international 2021 report: paying for views
Transpareny international 2021 report: paying for views
 
2020 IIS global concerns report
2020 IIS global concerns report2020 IIS global concerns report
2020 IIS global concerns report
 
What North America’s top finance executives are thinking - and doing
What North America’s top finance  executives are thinking - and doingWhat North America’s top finance  executives are thinking - and doing
What North America’s top finance executives are thinking - and doing
 
/freedom in thw World 2020
/freedom in thw World 2020/freedom in thw World 2020
/freedom in thw World 2020
 
Women, Business and the Law 2021
Women, Business and the Law 2021Women, Business and the Law 2021
Women, Business and the Law 2021
 
Oecd Competition Trends 2020
Oecd Competition Trends 2020Oecd Competition Trends 2020
Oecd Competition Trends 2020
 
Long-erm Care and Health Care Insurance in OECD and Other Countries
Long-erm Care and Health Care Insurance in OECD and Other CountriesLong-erm Care and Health Care Insurance in OECD and Other Countries
Long-erm Care and Health Care Insurance in OECD and Other Countries
 
Global insurance market trends 2020
Global insurance market trends 2020Global insurance market trends 2020
Global insurance market trends 2020
 
OECD: Artificial Intelligence's impact on the labour market
OECD: Artificial Intelligence's impact on the labour marketOECD: Artificial Intelligence's impact on the labour market
OECD: Artificial Intelligence's impact on the labour market
 
What happened to jobs at high risk of automation?
What happened to jobs at high risk of automation?What happened to jobs at high risk of automation?
What happened to jobs at high risk of automation?
 
Prescription drug prices in U.S. more than 2.5 times higher than in other cou...
Prescription drug prices in U.S. more than 2.5 times higher than in other cou...Prescription drug prices in U.S. more than 2.5 times higher than in other cou...
Prescription drug prices in U.S. more than 2.5 times higher than in other cou...
 
‘A circular nightmare’: Short-staffed nursing homes spark Covid-19 outbreaks,...
‘A circular nightmare’: Short-staffed nursing homes spark Covid-19 outbreaks,...‘A circular nightmare’: Short-staffed nursing homes spark Covid-19 outbreaks,...
‘A circular nightmare’: Short-staffed nursing homes spark Covid-19 outbreaks,...
 
Helping people stay in their homes tied to fewer Covid-19 cases
Helping people stay in their homes tied to fewer Covid-19 casesHelping people stay in their homes tied to fewer Covid-19 cases
Helping people stay in their homes tied to fewer Covid-19 cases
 

Recently uploaded

Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan 087776558899
 
Physiologic Anatomy of Heart_AntiCopy.pdf
Physiologic Anatomy of Heart_AntiCopy.pdfPhysiologic Anatomy of Heart_AntiCopy.pdf
Physiologic Anatomy of Heart_AntiCopy.pdf
MedicoseAcademics
 
Difference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac MusclesDifference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac Muscles
MedicoseAcademics
 

Recently uploaded (20)

Part I - Anticipatory Grief: Experiencing grief before the loss has happened
Part I - Anticipatory Grief: Experiencing grief before the loss has happenedPart I - Anticipatory Grief: Experiencing grief before the loss has happened
Part I - Anticipatory Grief: Experiencing grief before the loss has happened
 
HISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptx
HISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptxHISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptx
HISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptx
 
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptxCreeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
 
ABO Blood grouping in-compatibility in pregnancy
ABO Blood grouping in-compatibility in pregnancyABO Blood grouping in-compatibility in pregnancy
ABO Blood grouping in-compatibility in pregnancy
 
Drug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptxDrug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptx
 
VIP ℂall Girls Kothanur {{ Bangalore }} 6378878445 WhatsApp: Me 24/7 Hours Se...
VIP ℂall Girls Kothanur {{ Bangalore }} 6378878445 WhatsApp: Me 24/7 Hours Se...VIP ℂall Girls Kothanur {{ Bangalore }} 6378878445 WhatsApp: Me 24/7 Hours Se...
VIP ℂall Girls Kothanur {{ Bangalore }} 6378878445 WhatsApp: Me 24/7 Hours Se...
 
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
 
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATRO
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATROMOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATRO
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATRO
 
Physiologic Anatomy of Heart_AntiCopy.pdf
Physiologic Anatomy of Heart_AntiCopy.pdfPhysiologic Anatomy of Heart_AntiCopy.pdf
Physiologic Anatomy of Heart_AntiCopy.pdf
 
TEST BANK For Guyton and Hall Textbook of Medical Physiology, 14th Edition by...
TEST BANK For Guyton and Hall Textbook of Medical Physiology, 14th Edition by...TEST BANK For Guyton and Hall Textbook of Medical Physiology, 14th Edition by...
TEST BANK For Guyton and Hall Textbook of Medical Physiology, 14th Edition by...
 
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...
 
VIP ℂall Girls Arekere Bangalore 6378878445 WhatsApp: Me All Time Serviℂe Ava...
VIP ℂall Girls Arekere Bangalore 6378878445 WhatsApp: Me All Time Serviℂe Ava...VIP ℂall Girls Arekere Bangalore 6378878445 WhatsApp: Me All Time Serviℂe Ava...
VIP ℂall Girls Arekere Bangalore 6378878445 WhatsApp: Me All Time Serviℂe Ava...
 
See it and Catch it! Recognizing the Thought Traps that Negatively Impact How...
See it and Catch it! Recognizing the Thought Traps that Negatively Impact How...See it and Catch it! Recognizing the Thought Traps that Negatively Impact How...
See it and Catch it! Recognizing the Thought Traps that Negatively Impact How...
 
Top 10 Most Beautiful Chinese Pornstars List 2024
Top 10 Most Beautiful Chinese Pornstars List 2024Top 10 Most Beautiful Chinese Pornstars List 2024
Top 10 Most Beautiful Chinese Pornstars List 2024
 
Difference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac MusclesDifference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac Muscles
 
Face and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptxFace and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptx
 
Cardiac Output, Venous Return, and Their Regulation
Cardiac Output, Venous Return, and Their RegulationCardiac Output, Venous Return, and Their Regulation
Cardiac Output, Venous Return, and Their Regulation
 
Shazia Iqbal 2024 - Bioorganic Chemistry.pdf
Shazia Iqbal 2024 - Bioorganic Chemistry.pdfShazia Iqbal 2024 - Bioorganic Chemistry.pdf
Shazia Iqbal 2024 - Bioorganic Chemistry.pdf
 
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptxANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
 
Test bank for critical care nursing a holistic approach 11th edition morton f...
Test bank for critical care nursing a holistic approach 11th edition morton f...Test bank for critical care nursing a holistic approach 11th edition morton f...
Test bank for critical care nursing a holistic approach 11th edition morton f...
 

USA: Hepatitis A infections rise by nearly 300%

  • 1. Morbidity and Mortality Weekly Report Weekly / Vol. 68 / No. 18 May 10, 2019 INSIDE 416 Disparities in Incidence of Human Immunodeficiency Virus Infection Among Black and White Women — United States, 2010–2016 419 Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus — Fulton and DeKalb Counties, Georgia, 2002–2016 423 Vital Signs: Pregnancy-Related Deaths, United States, 2011–2015, and Strategies for Prevention, 13 States, 2013–2017 430 QuickStats Continuing Education examination available at https://www.cdc.gov/mmwr/cme/conted_info.html#weekly. U.S. Department of Health and Human Services Centers for Disease Control and Prevention Hepatitis Awareness Month and Testing Day — May 2019 May is designated as Hepatitis Awareness Month, and May 19 is Hepatitis Testing Day. Hepatitis B and hepatitis C, the most common types of viral hepatitis in the United States, can cause chronic infections, and many persons remain unaware of their infection until serious complications occur. In 2016, an estimated 862,000 and 2.4 million persons were living with hepatitis B and hepatitis C, respectively, despite availability of a vaccine and effective treatment for hepatitis B and a cure for hepatitis C (1,2). Although hepatitis A is preventable through vaccina- tion, multiple states have had outbreaks since 2016, with unprecedented large numbers of cases and person-to- person spread (primarily among persons who use drugs or experience homelessness). A report in this issue of MMWR summarizes this resurgence of hepatitis A among unvac- cinated adults at risk (3). New cases of hepatitis C are also increasing; during 2010–2016, they increased 3.5-fold, mostly among young adults (4). Recent increases in viral hepatitis infections, many attributed to surges in injection-drug use (4), high- light the importance of acknowledging and combatting the infectious disease consequences of the nation’s opioid crisis. References 1. Patel EU, Thio CL, Boon D, Thomas DL, Tobian AAR. Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011–2016. Clin Infect Dis 2019.https://doi.org/10.1093/cid/ciz001 2. Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013–2016. Hepatology 2019;69:1020–31. https://doi. org/10.1002/hep.30297 3. Foster M, Hofmeister MG, Kupronis BA, et al. Increase in hepatitis A virus infections—United States, 2013–2018. MMWR Morb Mortal Wkly Rep 2019;68:413–5. 4. CDC. Viral hepatitis surveillance—United States, 2016. Atlanta, GA: US Department of Health and Human Services, CDC; 2016. https://www.cdc.gov/hepatitis/statistics/2016surveillance/index.htm Increase in Hepatitis A Virus Infections — United States, 2013–2018 Monique A. Foster, MD1; Megan G. Hofmeister, MD1; Benjamin A. Kupronis, MPH1; Yulin Lin, MD1; Guo-Liang Xia, MD1; Shaoman Yin, PhD1; Eyasu Teshale, MD1 Hepatitis A virus (HAV) is primarily transmitted fecal-orally after close contact with an infected person (1); it is the most common cause of viral hepatitis worldwide, typically causing acute and self-limited symptoms, although rarely liver failure and death can occur (1). Rates of hepatitis A had declined by approximately 95% during 1996–2011; however, during 2016–2018, CDC received approximately 15,000 reports of HAV infections from U.S. states and territories, indicating a recent increase in transmission (2,3). Since 2017, the vast majority of these reports were related to multiple outbreaks of infections among persons reporting drug use or homeless- ness (4). In addition, increases of HAV infections have also occurred among men who have sex with men (MSM) and, to a much lesser degree, in association with consumption of imported HAV-contaminated food (5,6). Overall, reports of hepatitis A cases increased 294% during 2016–2018 compared
  • 2. Morbidity and Mortality Weekly Report 414 MMWR / May 10, 2019 / Vol. 68 / No. 18 US Department of Health and Human Services/Centers for Disease Control and Prevention The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027. Suggested citation: [Author names; first three, then et al., if more than six.] [Report title]. MMWR Morb Mortal Wkly Rep 2019;68:[inclusive page numbers]. Centers for Disease Control and Prevention Robert R. Redfield, MD, Director Anne Schuchat, MD, Principal Deputy Director Chesley L. Richards, MD, MPH, Deputy Director for Public Health Science and Surveillance Rebecca Bunnell, PhD, MEd, Director, Office of Science Barbara Ellis, PhD, MS, Acting Director, Office of Science Quality, Office of Science Michael F. Iademarco, MD, MPH, Director, Center for Surveillance, Epidemiology, and Laboratory Services MMWR Editorial and Production Staff (Weekly) Charlotte K. Kent, PhD, MPH, Editor in Chief Jacqueline Gindler, MD, Editor Mary Dott, MD, MPH, Online Editor Terisa F. Rutledge, Managing Editor Douglas W. Weatherwax, Lead Technical Writer-Editor Glenn Damon, Soumya Dunworth, PhD, Teresa M. Hood, MS, Technical Writer-Editors Martha F. Boyd, Lead Visual Information Specialist Maureen A. Leahy, Julia C. Martinroe, Stephen R. Spriggs, Tong Yang, Visual Information Specialists Quang M. Doan, MBA, Phyllis H. King, Terraye M. Starr, Moua Yang, Information Technology Specialists MMWR Editorial Board Timothy F. Jones, MD, Chairman Matthew L. Boulton, MD, MPH Virginia A. Caine, MD Katherine Lyon Daniel, PhD Jonathan E. Fielding, MD, MPH, MBA David W. Fleming, MD William E. Halperin, MD, DrPH, MPH Robin Ikeda, MD, MPH Phyllis Meadows, PhD, MSN, RN Jewel Mullen, MD, MPH, MPA Jeff Niederdeppe, PhD Patricia Quinlisk, MD, MPH Stephen C. Redd, MD Patrick L. Remington, MD, MPH Carlos Roig, MS, MA William Schaffner, MD Morgan Bobb Swanson, BS with 2013–2015. During 2016–2018, CDC tested 4,282 specimens, of which 3,877 (91%) had detectable HAV RNA; 565 (15%), 3,255 (84%), and 57 (<1%) of these specimens were genotype IA, IB, or IIIA, respectively. Adherence to the Advisory Committee on Immunization Practices (ACIP) recommendations to vaccinate populations at risk can help control the current increases and prevent future outbreaks of hepatitis A in the United States (7). Hepatitis A infections among persons who meet the Council of State andTerritorial Epidemiologists (CSTE) hepatitis A case definition (https://wwwn.cdc.gov/nndss/conditions/hepatitis- a-acute/) are notified to CDC through the National Notifiable Diseases Surveillance System (NNDSS). Cases reported to CDC through NNDSS during 2013–2018 were used to calculate percent change (2013–2015 versus 2016–2018) by state and mapped using RStudio software (version 1.2.1335; RStudio, Inc.). Serum specimens from CSTE confirmed cases submitted to the CDC laboratory were tested for HAV RNA by polymerase chain reaction, and isolated virus was amplified to characterize a 315–base-pair fragment of the VP1/P2B region, which defines the genotype of the virus. Overall, reports of hepatitis A cases increased 294% during 2016–2018 compared with 2013–2015 (Figure). Eighteen states had lower case counts during 2016–2018 compared with 2013–2015. Nine states and Washington, DC had an increase of approximately 500%. During 2013–2018, 4,508 HAV anti-immunoglobulin M–positive specimens under- went additional testing at CDC. During 2013–2015, 226 specimens underwent additional testing, of which 197 (87%) had detectable HAV RNA; of the RNA-positive specimens, 76 (39%), 121 (61%), and 0 (0%) tested positive for a genotype IA, IB, or IIIA viral strain, respectively. In comparison, 4,282 specimens were tested by CDC during 2016–2018, of which 3,877 (91%) had detectable HAV RNA; 565 (15%), 3,255 (84%), and 57 (<1%) of these specimens were genotype IA, IB, or IIIA, respectively. Discussion The number of hepatitis A infections reported to CDC increased during 2016–2018, along with the number of specimens from infected persons submitted to CDC for additional testing. In the past, outbreaks of hepatitis A virus infections occurred every 10–15 years and were associated with asymptomatic children (8). With the widespread adop- tion of universal childhood vaccination recommendations (https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5507a1. htm), asymptomatic children are no longer the main drivers of hepatitis A outbreaks (3,9). Although the overall incidence rate of HAV infections has decreased within all age groups, a large population of susceptible, unvaccinated adults who were not infected by being exposed to the virus during childhood remain vulnerable to infection by contaminated foods (typi- cally imported from countries with endemic HAV transmis- sion) and recently, on a much larger scale, through behaviors that increase risk for infection in certain vulnerable popula- tions, such as drug use (3).
  • 3. Morbidity and Mortality Weekly Report MMWR / May 10, 2019 / Vol. 68 / No. 18 415US Department of Health and Human Services/Centers for Disease Control and Prevention FIGURE. Percent change in reported hepatitis A infections, by state — National Notifiable Diseases Surveillance System, United States, 2013–2015 and 2016–2018* >500 >100–500 >0–100 −100–0 DC Abbreviation: DC = District of Columbia. * 2017 and 2018 case counts are provisional. Increasingly, molecular epidemiology is employed by public health laboratories to better characterize hepatitis A transmis- sion patterns. When combined with reliable epidemiologic data, these laboratory data can be used to identify transmission networks and confirm the source of exposure during common- source outbreaks, facilitating prompt and effective public health response. Historically, genotype IA has been the most common genotype circulating in North and South America. During 2013–2018, HAV genotype IB predominated in the United States. Increasing numbers of genotype IIIA were seen, a genotype that is considered rare in the United States. Decreasing new infections from hepatitis A virus can be achieved and sustained by maintaining a high level of popu- lation immunity through vaccination. There is no universal vaccination recommendation for adults in the United States; however, ACIP does recommend vaccination for adults who plan travel to HAV-endemic countries, MSM, persons who use drugs, persons with chronic liver disease, and recently, persons experiencing homelessness (7). Continued efforts to increase hepatitis A vaccination coverage among the ACIP- recommended risk groups is vital to halting the current hepa- titis A outbreaks and reducing overall hepatitis A incidence in the United States. Acknowledgments Members of the Division of Viral Hepatitis Laboratory, Division of Viral Hepatitis HAV Incident Management Team, Food and Drug Administration CORE Signals Teams; state and local health departments; medical and mental health partners; corrections partners; syringe service providers. Summary What is already known about this topic? Hepatitis A is a vaccine-preventable viral infection of the liver that is primarily transmitted through consumption of micro- scopic amounts of feces. What is added by this report? During 2016–2018, reports of hepatitis A infections in the United States increased by 294% compared with 2013–2015, related to outbreaks associated with contaminated food items, among men who have sex with men, and primarily, among persons who report drug use or homelessness. What are the implications for public health practice? Increasing vaccination among groups at risk for hepatitis A infection might halt ongoing outbreaks and prevent future outbreaks. 1Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC. Corresponding author: Monique A. Foster, ydg9@cdc.gov, 404-718-8561. All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed. References 1. Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: epidemiology and prevention in developing countries. World J Hepatol 2012;4:68–73. https://doi.org/10.4254/wjh.v4.i3.68 2. CDC. Viral hepatitis surveillance, United States 2016. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://www.cdc. gov/hepatitis/statistics/2016surveillance/pdfs/2016HepSurveillanceRpt.pdf 3. CDC. National notifiable infectious diseases: weekly tables, 2018. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https:// wonder.cdc.gov/nndss/static/2018/52/2018-52-table2H-H.pdf 4. Foster M, Ramachandran S, Myatt K, et al. Hepatitis A virus outbreaks associated with drug use and homelessness—California, Kentucky, Michigan, and Utah, 2017. MMWR Morb Mortal Wkly Rep 2018;67:1208–10. https://doi.org/10.15585/mmwr.mm6743a3 5. Viray MA, Hofmeister MG, Johnston DI, et al. Public health investigation and response to a hepatitis A outbreak from imported scallops consumed raw—Hawaii, 2016. Epidemiol Infect 2018;147:1–8. 6. Latash J, Dorsinville M, Del Rosso P, et al. Notes from the field: increase in reported hepatitis A infections among men who have sex with men— New York City, January–August 2017. MMWR Morb Mortal Wkly Rep 2017;66:999–1000. https://doi.org/10.15585/mmwr.mm6637a7 7. Doshani M, Weng M, Moore KL, Romero JR, Nelson NP. Recommendations of the Advisory Committee on Immunization Practices for use of hepatitis A vaccine for persons experiencing homelessness. MMWR Morb Mortal Wkly Rep 2019;68:153–6. https://doi. org/10.15585/mmwr.mm6806a6 8. MurphyTV, Denniston MM, Hill HA, et al. Progress toward eliminating hepatitis A disease in the United States. MMWR Suppl 2016;65:29–41. https://doi.org/10.15585/mmwr.su6501a6 9. Klevens RM, Denniston MM, Jiles-Chapman RB, Murphy TV. Decreasing immunity to hepatitis A virus infection among US adults: findings from the National Health and Nutrition Examination Survey (NHANES), 1999–2012. Vaccine 2015;33:6192–8. https://doi. org/10.1016/j.vaccine.2015.10.009